<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969733</url>
  </required_header>
  <id_info>
    <org_study_id>2009_05/0943</org_study_id>
    <secondary_id>2009-017682-33</secondary_id>
    <nct_id>NCT02969733</nct_id>
  </id_info>
  <brief_title>The Interest of the Xylocaine® and Ketamine on the Management of Acute and Chronic Ain After Colectomy by Laparoscopy</brief_title>
  <acronym>KETALIDO</acronym>
  <official_title>The Interest of the Xylocaine® and Ketamine on the Per and Postoperative Management of Acute and Chronic Postoperative Pain After Colectomy by Laparoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent clinical studies in abdominal surgery have shown that the use of Xylocaine®
      parenterally intraoperative at plasma concentrations below the toxic threshold of 5 .mu.g /
      ml, had an analgesic effect and decreased postoperative morphine consumption.

      This study aims to evaluate the activity of Xylocaine® and ketamine separately administered
      parenterally, in terms of postoperative morphine consumption and decrease incidences of
      postoperative chronic pain at 3 and 6 months after laparoscopic colectomy compared the
      placebo group.

      The evaluation of the intensity of postoperative pain, hyperalgesia perished skin surface
      scarring) and pain perception threshold by Pain Matcher® confirm or not the predictive nature
      of these criteria in the occurrence of chronic pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>During the first 24 postoperative hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>All 6 hours during the 48 postoperative hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale score</measure>
    <time_frame>All 2 hours during the first 24 postoperative hours and all 6 hours during the 48 postoperative hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electric nociception threshold measured by PainMatcher</measure>
    <time_frame>All 2 hours during the first 24 postoperative hours and all 6 hours during the 48 postoperative hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperalgesia of peri-scar (in cm²) with a von Frey filament (pressure of 10 grams</measure>
    <time_frame>At 2 days after postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire Douleur de Saint-Antoine (QDSA) ,</measure>
    <time_frame>at 3 months, at 6 months</time_frame>
    <description>evaluation with validated scores for chronic and neuropathic pains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire d'Evaluation des Douleurs Neuropathiques (QEDN),</measure>
    <time_frame>at 3 months, at 6 months</time_frame>
    <description>evaluation with validated scores for chronic and neuropathic pains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time physiological function recovery</measure>
    <time_frame>During the first 24 postoperative hours</time_frame>
    <description>Ability to drink, to eat, to urinate, to walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>At 5 days after postoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Xylocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic saline serum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>isotonic saline serum intravenous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylocaine</intervention_name>
    <description>Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.</description>
    <arm_group_label>Xylocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline serum intravenous administration</intervention_name>
    <arm_group_label>isotonic saline serum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Surgery: segmental or total colectomy performed by laparoscopy

          -  Anesthesia state 1 and 3

        Exclusion Criteria:

          -  Patients classified Anesthesia state 4 or 5

          -  Allergy or intolerance to any of the products used in the protocol

          -  Creatinine clearance calculated by the Cockcroft formula below 50 ml / min

          -  Hepatocellular insufficiency

          -  Severe heart failure

          -  Peptic ulcer

          -  Chronic inflammatory bowel disease (IBD)

          -  Previous history of epilepsy or seizures

          -  Surgery emergency, palliative surgery, revision surgery

          -  Chronic pain requiring regular intake of analgesics include opioids

          -  Patients treated with lidocaine patch

          -  Psychic Disorder

          -  Additive Conduct vis-à-vis alcohol or mind-altering substances

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Lebuffe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU, Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative analgesia</keyword>
  <keyword>PainMatcher</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

